Cancer patients with blood types A, B, and AB appear to have a greater risk of cancer-related blood clots as compared with patients who have type O. (Blood Advances)
Male sex hormones' interaction with T cells may explain why women respond better to cancer immunotherapy for tumors unrelated to reproductive organs. (Ohio State University, Science Immunology)
In a study involving preclinical models, CAR T cells combined with an oncolytic virus showed promise for targeting and treating solid tumors. (Mayo Clinic, Science Translational Medicine)
TG Therapeutics announced voluntary withdrawal of its biologics license application/supplemental new drug application for the U2 combination (ublituximab plus umbralisib [Ukoniq]) for chronic lymphocytic leukemia and small lymphocytic lymphoma after an updated analysis of a randomized trial showed a continual survival imbalance.
Nektar Therapeutics and Bristol Myers Squibb jointly announced termination of a clinical development program involving bempegaldesleukin and nivolumab (Opdivo) after planned interim analyses of two late-stage clinical trials in renal cell carcinoma and bladder cancer showed no significant improvement in outcomes versus control arms.
Genmab and AbbVie announced that a phase I/II trial of the bispecific antibody epcoritamab for relapsed/refractory large B-cell lymphoma exceeded the prespecified threshold for efficacy, showing an overall response rate of 63.1%.
The FDA has lifted a partial clinical hold on studies of the investigational drug magrolimab plus azacitidine in acute myelogenous leukemia and myelodysplastic syndrome, Gilead Sciences announced.
Curis announced that the FDA has placed a partial clinical hold on a phase I/II trial of the IRAK-4 kinase inhibitor emavusertib in patients with lymphoma, following the company's voluntary pause in enrollment for the trial after the FDA previously placed a partial hold on a leukemia trial of the drug.
GlaxoSmithKline agreed to purchase Sierra Oncology for $1.9 billion -- a 39% premium -- to expand its presence in the oncology market. (Bloomberg)
Restricting access to the nutrient methionine might help improve outcomes in diffuse midline glioma, a type of pediatric brain cancer. (University of Pittsburgh, Children's Hospital of Pittsburgh)
By: Charles Bankhead (MedPage Today).
Image: Medical Xpress.
Broadcast: FM.